Status:
UNKNOWN
Ciclosporin A and Acute Myocardial Infarction
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
PHASE3
Brief Summary
Beyond its immunosuppressive properties, ciclosporine A (CsA) can also inhibit the opening of a mitochondrial mega-channel called the permeability transition pore (mPTP). Opening of the mPTP plays a k...
Eligibility Criteria
Inclusion
- Male and female patients, aged more than 18, with suspected first acute myocardial infarction
- Within 12 hours of the onset of chest pain
- With a need for emergency revascularization by angioplasty. Patients must display a fully occluded (TIMI zero flow) culprit coronary artery, absence of visible collaterals and exhibit TIMI flow \>2 after direct stenting by angioplasty.
Exclusion
- Hypersensibility to ciclosporine A
- Cardiac arrest or cardiogenic shock
- Immunosuppressive disease (\< 6 months): cancers, lymphomas, positive serology for HIV, hepatitis, etc.
- Known renal failure or serum creatinine \> 120 µmole/l at admission
- Liver failure
- Uncontrolled hypertension
- Current pregnancy or women without contraception
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00403728
Start Date
September 1 2004
Last Update
April 27 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Michel Ovize
Lyon, France, 69677